Essential Premium

Hedge Funds Look for Rare IPO to Extend Biopharma Rally

Investors hope the impending biopharma public offering is as successful as the summer’s most recent deals.

Private Credit Forum - Texas

November 9-10, 2026 | Hotel ZaZa Austin Downtown

With Oil Prices Hitting ‘Scary Numbers,’ Conning Warns of Inflationary ‘Bleed-Through’

“A hornet's nest has been poked, and this is not going to be quick,” says North America CIO Cindy Beaulieu of the war in Iran or its aftereffects.

Sponsored

Why Flat Gold During Inflation Points to Fed Action

The Evolving Role of PE in Portfolios

Podcast- Comprehensive, Not Commoditized: The Key to Traditional Middle Market Underwriting

Whale Rock Makes Rare VC Bet on Harvey at $15.5B Valuation

The value of the legal AI startup has climbed five-fold in 19 months, with fresh money from Whale Rock and continued support from Coatue.

Related Content

Ken Tropin Plays the Long Game With Graham Capital

Michelle Celarier

Hedgies Eye Three Biopharma IPOs

Stephen Taub

Eighteen Months ago, I Wrote About How AI Agents Could Be Used to Run an Entire Investment Business

Angelo Calvello

5th Annual Sub-Advisory Central Roundtable

November 3-4, 2026 | Park Hyatt Chicago

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram